Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Regulated mRNA Transport02:22

Regulated mRNA Transport

In eukaryotes, transcription and translation are compartmentalized; an mRNA is first synthesized in the nucleus and then selectively transported to the cytoplasm for protein synthesis. Before transport, a pre-mRNA undergoes several steps of post-transcriptional modifications including splicing, 5' capping, and the addition of a poly-adenine tail. Various proteins bind to the pre-mRNA during these modifications. The mRNA transport takes place with the help of multiple proteins playing specific...
Regulated mRNA Transport02:22

Regulated mRNA Transport

In eukaryotes, transcription and translation are compartmentalized; an mRNA is first synthesized in the nucleus and then selectively transported to the cytoplasm for protein synthesis. Before transport, a pre-mRNA undergoes several steps of post-transcriptional modifications including splicing, 5' capping, and the addition of a poly-adenine tail. Various proteins bind to the pre-mRNA during these modifications. The mRNA transport takes place with the help of multiple proteins playing specific...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Equity in medical school interviews: a cross-sectional analysis of school type, gender, and widening participation status.

BMC medical education·2026
Same author

Ethnic differences in specialty destinations in UK medicine: a repeated cross-sectional analysis of secondary data.

Journal of the Royal Society of Medicine·2026
Same author

Exploring student perceptions of integrating mixed reality with cadaveric teaching in undergraduate neuroanatomy education: A qualitative study.

Anatomical sciences education·2026
Same author

High-purity stem cell-derived β-cells recapitulate key transcriptional and functional features of human islets.

bioRxiv : the preprint server for biology·2026
Same author

Validity of constructed-response situational judgement tests in health professions education: A systematic review and meta-analysis.

Medical education·2026
Same author

Cystic fibrosis related diabetes - viewpoints on three research areas presented at the 20th ECFS basic science conference.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026

Related Experiment Video

Updated: May 30, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Rimonabant: From RIO to Ban.

Amir H Sam1, Victoria Salem, Mohammad A Ghatei

  • 1Section of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Hammersmith Hospital, Imperial College London, Du Cane Road, London W12 0NN, UK.

Journal of Obesity
|July 21, 2011
PubMed
Summary

Endocannabinoid antagonists like Rimonabant showed promise for obesity and metabolic syndrome but were withdrawn due to severe side effects, including mood disorders. This highlights challenges in developing centrally acting weight loss drugs.

More Related Videos

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery
07:12

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Published on: April 8, 2021

Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)
09:38

Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)

Published on: September 5, 2025

Related Experiment Videos

Last Updated: May 30, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery
07:12

Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery

Published on: April 8, 2021

Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)
09:38

Updated Protocol for the Assembly and Use of the Minibioreactor Array (MBRA)

Published on: September 5, 2025

Area of Science:

  • Pharmacology
  • Metabolic Disorders
  • Drug Development

Background:

  • Endocannabinoid antagonism was a promising therapeutic target for obesity and metabolic syndrome.
  • Rimonabant, a CB1 receptor antagonist, demonstrated weight loss and metabolic improvements in trials.
  • Concerns regarding severe side effects, particularly psychiatric issues, led to Rimonabant's market withdrawal.

Purpose of the Study:

  • To review the history and implications of Rimonabant's development and withdrawal.
  • To contextualize recent FDA rejections of centrally acting weight loss drugs.

Main Methods:

  • Literature review of Rimonabant's clinical trials and post-marketing data.
  • Analysis of the pharmacological rationale for CB1 antagonism in metabolic disease.
  • Examination of regulatory actions concerning centrally acting weight loss agents.

Main Results:

  • Rimonabant offered significant weight loss and metabolic benefits but was associated with severe psychiatric side effects.
  • The withdrawal of Rimonabant created a cautionary precedent for similar drug development.
  • Recent FDA rejections underscore the persistent challenges in this therapeutic area.

Conclusions:

  • The development of effective and safe treatments for obesity and metabolic syndrome remains a significant challenge.
  • Balancing efficacy with safety, especially regarding central nervous system effects, is critical for drug approval.
  • Further research into alternative mechanisms or improved drug delivery may be necessary.